Search Results

ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.

ARS Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion on the application for marketing authorization for EURneffy® and recommended related market authorization in the European Union for the emergency treatment of allergic reactions.

Arthrosi Therapeutics, Inc. announced new positive clinical data from its phase 2 AR882-203 study in patients with tophaceous gout.

ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, reported business updates and financial results for the first quarter of 2024.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the publication of results from the ALIGN-AR Pivotal Trial in The Lancet.

ARS Pharmaceuticals, Inc. today announced its participation in the Leerink Partners Global Biopharma Conference 2024 being held March 11-13, 2024 in Miami, Florida.